Determination of irinotecan, SN-38 and SN-38 glucuronide using HPLC/MS/MS: Application in a clinical pharmacokinetic and personalized medicine in colorectal cancer patients

  • J Clin Lab Anal. 2018 Jan;32(1):e22217. doi: 10.1002/jcla.22217.
Chalirmporn Atasilp  1  2 ,  Pichai Chansriwong  3 ,  Ekapob Sirachainan  3 ,  Thanyanan Reungwetwattana  3 ,  Apichaya Puangpetch  1  2 ,  Santirhat Prommas  1  2 ,  Suwannee Sirilerttrakul  3 ,  Budsaba Rerkarmnuaychoke  4 ,  Sansanee Wongwaisayawan  5 ,  Chonlaphat Sukasem  1  2
Affiliations
  • 1. Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
  • 2. Laboratory for Pharmacogenomics, Clinical Pathology, Somdetch Phra Debharatana Medical Centre, Ramathibodi Hospital, Bangkok, Thailand.
  • 3. Division of Medical Oncology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
  • 4. Division of Human Genetics Laboratory, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
  • 5. Division of Anatomical Pathology, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
PMID: 28393405 DOI: 10.1002/jcla.22217
Abstract

Background: Irinotecan (CPT-11) is chemotherapy used mainly in the metastatic colorectal Cancer. The purpose of this study was to develop and validate the LC-MS/MS for the simultaneous determination of CPT-11, SN-38, and SN-38G.

Methods: A 100 μL of plasma was prepared after protein precipitation and analyzed on a C18 column using 0.1% acetic acid in water and 0.1% acetic acid in acetonitrile as mobile phases. The mass spectrometer worked with multiple reaction monitoring (MRM) in positive scan mode. The standard curves were linear on a concentration range of 5-10 000 ng/mL for CPT-11, 5-1000 ng/mL for SN-38, and 8-1000 ng/mL for SN-38G.

Results: In this assay, the intra and interday precision consisted of ≤9.11% and ≤11.29% for CPT-11, ≤8.70% and 8.31% for SN-38, and ≤9.90 and 9.64% for SN-38G.

Conclusion: This method was successfully used to quantify CPT-11, SN-38, and SN-38G and applied to a pharmacokinetic study.

Keywords
CPT-11; LC-MS/MS; SN-38; SN-38G; colorectal cancer.
Products